HCPLive » Schizophrenia
137 FOLLOWERS
The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more. HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific..
HCPLive » Schizophrenia
2d ago
EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials ..read more
HCPLive » Schizophrenia
1M ago
Acadia Pharmaceuticals decided to stop conducting further clinical trials with pimavanserin for negative symptoms of negative due to topline results ..read more
HCPLive » Schizophrenia
1M ago
Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores ..read more
HCPLive » Schizophrenia
2M ago
In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections ..read more
HCPLive » Schizophrenia
2M ago
Our January 2024 psychiatry month in review includes studies finding associations with depression, anxiety, and anorexia nervosa, as well as a phase 3 study looking into long-term safety of olanzapine, samidorphan ..read more
HCPLive » Schizophrenia
2M ago
A new study found patients with schizophrenia on lurasidone had an effect size change of 0.33 on the PANSS prosocial subscale, suggesting improvements in social functioning ..read more
HCPLive » Schizophrenia
2M ago
A new study found individuals aged 18 – 55 with treatment-resistant schizophrenia had significantly greater adverse events than individuals aged ≥ 55 years ..read more
HCPLive » Schizophrenia
3M ago
In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment ..read more
HCPLive » Schizophrenia
3M ago
A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period ..read more
HCPLive » Schizophrenia
4M ago
In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group ..read more